Chan Chun Sing, the current Singaporean Minister for Trade and Industry, has recently said that new cooperations between the state and pharma companies are necessary for keeping Singapore an international biomedical hub. He has also emphasized the current demand for the so-called precision drugs, which are to be made specifically for certain individuals (“personalized medicine”). According to him, Singapore is able to meet the demands of time in this area and keeps in touch with other countries. He has also stressed out that collaboration and trust-based relations between governmental structures, manufacturing corporations, and employees are of vital importance.
Mr Chan has made the speech at the opening of a new producing facility of GSK (UEN code can be found at uen.gov.sg), an international UK-headquartered pharmaceutical giant. The plant will feature a new technology which allows to ensure continuous manufacturing (CM), as a great alternative to traditional batch production. CM significantly shortens the time of producing medicines, from 6 months (in case of batch technique) to just 42 days. Products also have better quality and are produced by more compact equipment allowing to reduce carbon emissions by 3/4.
The first expected product is a new oral pill for anemia linked to chronic kidney illnesses. GSK will also produce key medications for HIV therapy with improved efficiency after the new manufacturing company formation in S-pore.